Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exce

Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosio

AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution

Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary eros

Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally stro

Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercializati

Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises th

Arkadios Wealth Advisors purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AM

Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the qua

Amneal Pharmaceuticals NASDAQ: AMRX reported second-quarter 2026 revenue of $796 million, up 10% fro

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks

Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06

Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.30 per share which beat the a

–  Q2 2026 Net Revenue of $796 million ; GAAP Net Income of $58 million ; Diluted Income per Share o

Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up t

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AM

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/m

BRIDGEWATER, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“A

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises th

BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“A

On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal&#3

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after recei

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significan

MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals tod

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-

3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, b

Overall Interim Findings (Entire Study Population, 214Patients; Six-Week Analysis)All 214 patients w

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announc

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight

Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars pla

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a diversifie

Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of C

UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy r

https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy

Amneal beats fourth-quarter earnings and revenue estimates, driven by CREXONT sales, and guides up t

Amneal Pharmaceuticals (NASDAQ:AMRX) is looking for FY2026 Adj EPS of $0.93-$1.03 vs $0.94 analyst e

Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.21 per share which beat the a

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announ